Compounding: Can FDA Afford The New Oversight It Wants?
FDA estimates the compounding user fee proposed in pending legislation would pay for about half the total cost of expanded oversight, but the agency would have to find budget authority dollars to fund significant portions of a new program.
You may also be interested in...
User fees, not appropriations, will make up the bulk of FDA’s human drug spending if President Obama’s FY 2014 budget comes to pass, a trend fueled by new user fee programs and cuts to taxpayer funding.
Twenty sponsors now have applications in the new review model, but none have reached the approval decision stage; industry officials say it still is too early to draw conclusions.
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.